We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Rapid POC Test for Diagnosis of Preeclampsia Could Prevent Unnecessary Hospitalization

By LabMedica International staff writers
Posted on 16 May 2022
Print article
Image: A new test relies on highly specific biomarkers to diagnose preeclampsia (Photo courtesy of Pexels)
Image: A new test relies on highly specific biomarkers to diagnose preeclampsia (Photo courtesy of Pexels)

Preeclampsia is a pregnancy disorder that can have devastating effects on the health of the mother and the unborn baby. Affecting 5-8% of all pregnancies, it is a rapidly progressive and potentially deadly condition. A correct diagnosis of the pregnancy disorder is currently time-consuming and, in many cases, inaccurate. Now, a fast and precise point-of-care test for preeclampsia is being developed that would provide diagnostic certainty and at the same time, save healthcare costs.

MOMM Diagnostics (Basel, Switzerland) is developing a rapid test for preeclampsia that would offer unprecedented sensitivity at the point-of-care. MOMM develops high-sensitivity rapid diagnostic tests. Immediate information during pregnancy check-ups will help doctors to optimize treatment, reduce stress and anxiety for expectant mothers, save lives and reduce costs. The rapid test for preeclampsia will be based on the company’s technology that combines the commercial advantage of lateral flow immunoassays, with the sensitivity of ELISA, and reader simplicity similar to blood glucose meters.

Since pregnant women regularly go to medical check-ups, the test can be carried out at the gynecologist without the need to send blood samples to a specialized diagnostics lab. The rapid screening test for preeclampsia will also spare expectant mothers the long wait for lab results. This will save valuable time and enable treatment to be started quickly. By providing diagnostic certainty, the test would also eliminate the possibility of false positive results by conventional tests that can create unnecessary anxiety for pregnant women.

Related Links:
MOMM Diagnostics 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
New
Automated Hematology Analyzer
Celltac Alpha MEK-1301/1302
New
Portable RT PCR Instrument
LineGene Mini S

Print article

Channels

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.